KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $4.4 billion.

  • Gilead Sciences' Operating Expenses fell 3327.32% to $4.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 billion, marking a year-over-year decrease of 3231.55%. This contributed to the annual value of $27.1 billion for FY2024, which is 3885.5% up from last year.
  • As of Q3 2025, Gilead Sciences' Operating Expenses stood at $4.4 billion, which was down 3327.32% from $4.6 billion recorded in Q2 2025.
  • Gilead Sciences' Operating Expenses' 5-year high stood at $11.0 billion during Q1 2024, with a 5-year trough of $3.5 billion in Q1 2021.
  • For the 5-year period, Gilead Sciences' Operating Expenses averaged around $5.1 billion, with its median value being $4.6 billion (2025).
  • As far as peak fluctuations go, Gilead Sciences' Operating Expenses soared by 13688.4% in 2024, and later tumbled by 5975.65% in 2025.
  • Quarter analysis of 5 years shows Gilead Sciences' Operating Expenses stood at $6.3 billion in 2021, then decreased by 18.75% to $5.1 billion in 2022, then rose by 7.42% to $5.5 billion in 2023, then fell by 7.0% to $5.1 billion in 2024, then fell by 13.19% to $4.4 billion in 2025.
  • Its Operating Expenses stands at $4.4 billion for Q3 2025, versus $4.6 billion for Q2 2025 and $4.4 billion for Q1 2025.